The Difference of Bax Protein Expression between Endometrioma and Ovarian Carcinoma

Chandran Frinaldo Saragih, Riza Rivany, Mohamad Fauzie Sahil, Fadjrir Fadjrir, Edy Ardiansyah, Muhammad Rizki Yaznil, Munauwarus Sarirah


Background: Endometriosis is a benign disease that has malignant properties such as genetic polymorphism, loss control of cell proliferation, infiltration, and local spread or to distant places. Several endometriosis studies linking endometrioma/ ovarian endometriosis with an increased risk of ovarian malignancy give rise to a transformation phenomenon of endometriotic cysts into malignancy. Bax is a pro apoptotic protein whose expression decreases in a malignancy. This decrease is related to the poor prognosis of endometrioma and ovarian carcinoma. This study was aimed to identify the expression and the difference of Bax expression between endometrioma and ovarian carcinoma.

Materials and Methods: Fifty of paraffin blocks of endometrioma tissue and ovarian carcinoma (serous, mucinous, clear cell, and endometrioid type) were examined by immunohistochemical using Bondmax Full Automatic with specific monoclonal antibody to identify Bax expression. The difference of Bax expression score between endometrioma tissue and ovarian carcinoma was tested by Mann-Whitney test with significant value was set at p<0.05.

Results: This study found that mean Bax expression score in endometrioma tissue and ovarian carcinoma was 3.88 and 3.72. No difference of Bax expression between endometrioma tissue and ovarian carcinoma (p>0.05). No difference of Bax expression between the clinical stages and histopathological types of ovarian carcinoma (p>0.05).

Conclusion: There are no statistically significant difference in Bax protein expression in ovarian cancer and endometrioma.

Keywords: Bax expression, endometrioma, ovarian carcinoma, apoptotic resistance


Full Text:



Speroff L, Fritz M. Clinical Gynecologic Endocrinology and Fertility. 8th ed. Philadelphia: Lippincott Williams & Wilkins; 2011.

Gelbaya T, Nardo L. Evidence-based management of endometrioma. Reprod Biomed Online. 2011; 23(1): 15-24, CrossRef.

Tzadik M, Purcell K, James M. Benign disorders of the ovaries & oviducts. In: DeCherney A, Nathan L, Laufer N, Roman A, editors. Current Diagnosis & Treatment Obstetrics and Gynecology. 10th ed. New York: Mc-Graw Hills Companies; 2007. p.654-60, article.

Jacoeb T, Hadisaputra W. Penanganan Endometriosis: Panduan klinis dan algoritme. Jakarta: Sagung Seto; 2009.

Varma R, Rollason T, Gupta J, Maher E. Endometriosis and the neoplastic process. Reproduction. 2004; 127(3): 293-304, CrossRef.

Nezhat F, Datta M, Hanson V, Pejovic T, Nezhat C, Nezhat C. The relationship of endometriosis and ovarian malignancy: a review. Fertil Steril. 2008; 90(5): 1559-70, CrossRef.

Pearce C, Templeman C, Rossing M, Lee A, Near A, Webb P, et al. Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case-control studies. Lancet Oncol. 2012; 13(4): 385-94, CrossRef.

Melin A, Lundholm C, Malki N, Swahn, M, Sparen P, Berggvist A. Endometriosis as a prognostic factor for cancer survival. Int J Cancer. 2011; 129(4): 948-55, CrossRef.

Munksgaard P, Blaakaer J. The association between endometriosis and ovarian cancer: a review of histological, genetic and molecular alterations. Gynecol Oncol. 2012; 124(1): 164–9, CrossRef.

Wieser F, Schneeberger C, Tong D, Tempfer C, Huber J, Wenzl R. PROGINS receptor gwnw polymorphism is associated with endometriosis. Fertil Steril2. 2002; 77(2): 309-12, CrossRef.

Gazvani R, Templeton A. New considerations for the pathogenesis of endometriosis. Int J Gynaecol Obs. 2002; 76(2): 117-26, CrossRef.

Wei J, William J, Bulun S. Endometriosis and ovarian cancer: a review of clinical, pathologic, and molecular aspects. Int J Gynaecol Pathol. 2011; 30(6): 553-68, CrossRef.

Meresman G, Vighi S, Buquet R, Contreras-Ortiz O, Tesone M, Rumi L. Apoptosis and expression of Bcl-2 and Bax in eutopic endometrium from women with endometriosis. Fertil Steril. 2000; 74(4): 760-6, CrossRef.

Bischoff F, Heard M, Simpson J. Somatic DNA alterations in endometriosis: high frequency of chromosome 17 and p53 loss in late-stage endometriosis. J Reprod Immunol. 2002; 55(1-2): 49-64, CrossRef.

Agic A, Djalali S, Diedrich K, Hornung D. Apoptosis in endometriosis. Gynecol Obs Invest. 2009; 68(4): 217-23, CrossRef.

Worley MJ, Welch WR, Berkowitz RS, Ng SW. Endometriosis-associated ovarian cancer: A review of pathogenesis. Int J Mol Sci. 2013; 14(3): 5367-79, CrossRef.

Dako. ER/PR pharmDX Interpretation Manual. Glostrup: Dako; 2007, article.

Fauvet R, Dufournet C, Poncelet C, Uzan C, Hugol D, Daraï E. Expression of pro-apoptotic (p53, p21, bax, bak and fas) and anti-apoptotic (bcl-2 and bcl-x) proteins in serous versus mucinous borderline ovarian tumours. J Surg Oncol. 2005; 92(4): 337-43, CrossRef.

Yoshikawa H, Jimbo H, Okada S, Matsumoto K, Onda T, Yasugi T, et al. Prevalence of endometriosis in ovarian cancer. Gynecol Obs Invest. 2000; 50(Supp 1): 11-7, CrossRef.

Brinton L, Gridley G, Persson I, Baron J, Berggvist A. Cancer risk after a hospital discharge diagnosis of endometriosis. Am J Obs Gynecol. 1997; 176(3): 572-9, CrossRef.

Boyraz G, Selcuk I, Yazıcıoğlu A, Tuncer Z. Ovarian carcinoma associated with endometriosis. Eur J Obstet Gynecol Reprod Biol. 2013; 170(1): 211-3, CrossRef.

Rossing M, Cushing-Haugen K, Wicklund K, Doherty J, Weiss N. Risk of epithelial ovarian cancer in relation to benign ovarian condition and ovarian surgery. Cancer Causes Control. 2008; 19(10): 1357-64, CrossRef.

Vercellini P, Scarfone G, Bolis G, Stellato G, Carinelli S, Crosignani P. Site of origin of epithelial ovarian cancer: the endometriosis connection. An Int J Obstet Gynaecol. 2000; 107(9): 1155-7, CrossRef.

Jimbo H, Yoshikawa H, Onda T, Yasugi T, Sakamoto A, Taketani Y. Prevalence of ovarian endometriosis in epithelial ovarian cancer. Int J Gynaecol Obs. 1997; 59(3): 245-50, CrossRef.

Fauvet R, Poncelet C, Hugol D, Lavaur A, Feldmann G, Dara E. Expression of apoptosis-related proteins in endometriomas and benign and malignant ovarian tumours. Virchows Arch. 2003; 443(1): 38-43, CrossRef.

Nezhat F, Kalir T. Comparative immunohistochemical studies of endometriosis lesions and endometriotic cysts. Fertil Steril. 2002; 78(4): 820-4, CrossRef.

Wehrli B, Krajewski S, Gascoyne R, Reed J, Gilks C. Immunohistochemical analysis of bcl-2, bax, mcl-1, and bcl-x expression in ovarian surface epithelial tumors. Int J Gynecol Pathol. 1998; 17(3): 255-60, CrossRef.

Nurcahyo RA. Studi Perbedaan Ekspresi BAX antara Endometriosis Ovarii (Endometrioma) dan Karsinoma Ovarii Serosum Diferensiasi Baik [Thesis]. Surakarta: Universitas Sebelas Maret; 2010, article.

Somigliana E, Vigano P, Parazzini F, Stoppelli S, Giambattista E, Vercellini P. Association between endometriosis and cancer: a comprehensive review and a critical analysis and epidemiologic evidence. Gynecol Oncol. 2006; 101(2): 331-41, CrossRef.

Aris A. Endometriosis-associated ovarian cancer: A ten-year cohort study of women living in the Estrie Region of Quebec, Canada. J Ovarian Res. 2010; 3(1): 2-6, CrossRef.

Marone M, Scambia G, Mozzetti S, Ferrandina G, Iacovella S, De Pasqua A, et al. Bcl-2. Bax, Bcl-XL, and Bcl-XS expression in normal and neoplastic ovarian tissues. Clin Cancer Res. 1998; 4(2): 517-24, article.

Schuyer M, van der Burg M, Henzen-Logmans S, Fieret J, Klijn J, Look M, et al. Reduced expression of BAX is associated with poor prognosis in patients with epithelial ovarian cancer: a multifactorial analysis of TP53, p21, BAX andBCL-2. Br J Cancer. 2001; 85(9): 1359-67, CrossRef.


Copyright (c)

Indexed by:




Cell and BioPharmaceutical Institute